Unknown Speaker

Well, could we identify embryos that have a problem before we actually transfer them? And then you'd only transfer the healthy embryos. And we make that transition in the 1990s.

So we go from being able to look at the embryo, thinking about transferring the embryo in a healthy context, to getting to a point where we can take the embryo and look at it and make a judgment about its quality and then decide to transfer or not. And now getting to the stage where we're thinking, well, while we're looking at this thing in the lab, why don't we just tinker with it?

So we go from being able to look at the embryo, thinking about transferring the embryo in a healthy context, to getting to a point where we can take the embryo and look at it and make a judgment about its quality and then decide to transfer or not. And now getting to the stage where we're thinking, well, while we're looking at this thing in the lab, why don't we just tinker with it?

So we go from being able to look at the embryo, thinking about transferring the embryo in a healthy context, to getting to a point where we can take the embryo and look at it and make a judgment about its quality and then decide to transfer or not. And now getting to the stage where we're thinking, well, while we're looking at this thing in the lab, why don't we just tinker with it?

Well, there's always risks to doing tinkering because the important thing about research is it's a step into the unknown. We don't actually know what we're going to do, what we're going to find. And that's true whether we're talking about patients enrolled in a clinical trial or whether we're talking about biological material in a laboratory.

Well, there's always risks to doing tinkering because the important thing about research is it's a step into the unknown. We don't actually know what we're going to do, what we're going to find. And that's true whether we're talking about patients enrolled in a clinical trial or whether we're talking about biological material in a laboratory.

Well, there's always risks to doing tinkering because the important thing about research is it's a step into the unknown. We don't actually know what we're going to do, what we're going to find. And that's true whether we're talking about patients enrolled in a clinical trial or whether we're talking about biological material in a laboratory.

So I think we need to appreciate that when we don't know, we don't know the good things or the potentially harmful things. And I think that's the context in which many people are worried about manipulating the human embryo, because if you've made a mistake, that mistake will be visited upon generation after generation after generation.

So I think we need to appreciate that when we don't know, we don't know the good things or the potentially harmful things. And I think that's the context in which many people are worried about manipulating the human embryo, because if you've made a mistake, that mistake will be visited upon generation after generation after generation.

So I think we need to appreciate that when we don't know, we don't know the good things or the potentially harmful things. And I think that's the context in which many people are worried about manipulating the human embryo, because if you've made a mistake, that mistake will be visited upon generation after generation after generation.

You're going in, you're cutting the DNA, and you could just mess things up.

You're going in, you're cutting the DNA, and you could just mess things up.

You're going in, you're cutting the DNA, and you could just mess things up.

If you were to look at it globally, I would say to you about half of the world's countries explicitly prohibit this kind of research. No country explicitly permits this kind of research. And there are a number of countries where they haven't bothered to write anything about this research. And just to put that in perspective, I mean, you can think about small islands.

If you were to look at it globally, I would say to you about half of the world's countries explicitly prohibit this kind of research. No country explicitly permits this kind of research. And there are a number of countries where they haven't bothered to write anything about this research. And just to put that in perspective, I mean, you can think about small islands.

If you were to look at it globally, I would say to you about half of the world's countries explicitly prohibit this kind of research. No country explicitly permits this kind of research. And there are a number of countries where they haven't bothered to write anything about this research. And just to put that in perspective, I mean, you can think about small islands.

My family comes from Barbados. It's a very small island in the Caribbean. Why would they take up any of their policy effort to try to regulate in this space? It's not research they're likely to pursue.

My family comes from Barbados. It's a very small island in the Caribbean. Why would they take up any of their policy effort to try to regulate in this space? It's not research they're likely to pursue.

My family comes from Barbados. It's a very small island in the Caribbean. Why would they take up any of their policy effort to try to regulate in this space? It's not research they're likely to pursue.

I think it does. And I think it's going to make for some very interesting and difficult conversations, conversations we need to have. So it's absolutely true that there's a lot of enthusiasm for what looks like a successful treatment for a person who otherwise would have had a number of complicated health challenges. As we continue to develop that, you will have people say, Why are we doing this?